MedTrace Logo

S-ketamin Premedication in Pediatric EENT Surgery

NCT04757675 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2022-04-27

No results posted yet for this study

Summary

We aim to investigate the effects of premedication (intranasal or intravenous administration) of s-ketamin, dexmedetomidine, and combination for premedication in children undergoing ENT surgery.

Conditions

  • Emotions
  • Separation Anxiety
  • Pain, Procedural

Interventions

DRUG

S-ketamine 0.3

0.3 μg/kg intravenous injection s-ketamin

DRUG

S-ketamine 0.5

0.5 μg/kg intravenous injection s-ketamin

DRUG

S-ketamine 2

2 μg/kg intranasal s-ketamin

DRUG

S-ketamine 1+Dexmedetomidine 1

1 μg/kg intranasal s-ketamin + 1 μg/kg intranasal dexmedetomidine

DRUG

S-ketamine 0.5 +Dexmedetomidine 2

0.5 μg/kg intranasal s-ketamin + 2 μg/kg intranasal dexmedetomidine

Sponsors & Collaborators

  • Eye & ENT Hospital of Fudan University

    lead OTHER

Principal Investigators

  • Hui Qiao, M.D. · Eye and ENT Hospital of Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2021-09-01
Completion
2022-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04757675 on ClinicalTrials.gov